Stem cell therapy of COVID-19 related ARDS

Purpose and goal:

The aim of the project was to investigate, in a preclinical animal model, the optimal dose and mechanisms of action of the stem cell product XSTEM for the treatment of the severe lung complication ARDS (Acute Respiratory Distress Syndrome), which can affect Covid-19 patients. The project has achieved the goal of demonstrating safety and efficacy of the selected dose of XSTEM in the ARDS model, protecting effect of XSTEM on the lung tissue and identifying cellular and molecular mechanisms of action. With these results, XSTEM is ready for clinical studies and commercialization.

Expected results and effects:

Our studies have shown that a specific dose of XSTEM (integrin alpha10-selected mesenchymal stem cells) has a therapeutic effect in a pig model for ARDS. Histological analyzes have demonstrated that XSTEM protects the lung tissue from damage, which explains improved blood circulation and oxygenation of the blood compared to the control. The studies also show that the mechanisms of action of XSTEM include a reduction of inflammatory cells and regulation of inflammatory cytokines and also reduced coagulation of the blood. These results support XSTEM for treatment of ARDS patients.

Approach and implementation:

The project was carried out in collaboration between Xintela, Region Skåne and Lund University. Xintela has produced and quality assured the stem cell product XSTEM, in its GMP production facility, Region Skåne has investigated clinical, cellular and molecular effects of XSTEM in a clinically relevant animal model for ARDS and Lund University has performed histological analysis of the lung tissues in XSTEM treated and untreated animals. The results are compiled for a joint publication.